Login to Your Account



ON-TARGET, ON-TUMOR

More specific targeting opens door to wider car T-cell use

By Anette Breindl
Science Editor

Wednesday, December 11, 2013
Engineered T cells are probably the most promising therapy that regularly sends its recipients to the intensive care unit. Their toxicity is due to two separate issues: on-target/off-tumor activity and cytokine release syndrome, or cytokine storm. Now, scientists have found a way to reduce on-target/off-tumor activity. Indirectly, their method may also help reduce the cytokine storm. At the annual meeting of the American Society of Hematology, which ended earlier this week, the excitement about engineered T cells was palpable.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription